Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the role of insulin resistance in cardiovascular risk and suggests that lifestyle changes may be more beneficial than metformin in managing polycystic ovary syndrome; it reports no new clinical results.

This study concluded that clomiphene citrate is generally preferred over metformin for inducing ovulation in obese women with PCOS, despite low-quality evidence indicating metformin may be superior to placebo for live births.

This review highlights that while sonidegib and vismodegib offer promising treatment options for advanced basal cell carcinoma, their use is often limited by treatment-emergent adverse events, which can be managed through protocol modifications and supportive interventions.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This study found that oral contraceptives containing cyproterone acetate significantly improved the overall quality of life in polycystic ovary syndrome patients after six months, compared to those containing levonorgestrel.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Ritlecitinib works well and is safe for treating alopecia areata.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study found that silencing the circular RNA circNlgn in mice reduced doxorubicin-induced cardiofibrosis and cardiomyocyte apoptosis, suggesting potential therapeutic strategies for minimizing heart-related side effects in cancer treatment.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This study found that men with early-onset androgenic alopecia may be partially resistant to the cardiometabolic benefits of bromocriptine compared to those with normal hair growth.

In this study, researchers developed and tested a novel peptide, AMHR2BP, which mimics the function of Anti-Müllerian hormone to protect ovarian follicles in mice, showing promise for preserving ovarian health during chemotherapy without causing toxicity.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

In this study, researchers developed ionizable coenzyme Q10-engineered lipid/fiber microplexes that restored mitochondrial-ribosomal function and enhanced mRNA translation in senescent cells, leading to increased hair follicle density and bone formation in mouse models compared to conventional lipid nanoparticles.

In this randomized trial, bicalutamide was found to improve hair count and shaft diameter more than spironolactone in women with Female Pattern Hair Loss over 24 weeks, although no significant differences were observed in clinical endpoints between the two treatments.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

This study found that applying a 1% BOI lotion improved hair density and thickness in patients with mild pattern hair loss over six months.

This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice.

This study observed that cyclosporine A significantly alters sex hormone levels in both pre- and post-menopausal women with primary biliary cirrhosis.

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

This article reviews clinical and treatment aspects of hyperandrogenism in women, emphasizing the roles of diagnostic practices, combined oral contraceptives, and cyproterone acetate, but introduces no new findings.

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.

This study concluded that Buserelin can effectively inhibit gonadal activity in children with central precocious puberty over 18 months, potentially improving final height predictions with prolonged treatment.